Teva Pharmaceutical Industries Receivables 2010-2024 | TEVA

Teva Pharmaceutical Industries receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • Teva Pharmaceutical Industries receivables for the quarter ending June 30, 2024 were $3.766B, a 6.41% increase year-over-year.
  • Teva Pharmaceutical Industries receivables for 2023 were $3.408B, a 7.79% decline from 2022.
  • Teva Pharmaceutical Industries receivables for 2022 were $3.696B, a 18.39% decline from 2021.
  • Teva Pharmaceutical Industries receivables for 2021 were $4.529B, a 1.14% decline from 2020.
Teva Pharmaceutical Industries Annual Receivables
(Millions of US $)
2023 $3,408
2022 $3,696
2021 $4,529
2020 $4,581
2019 $5,676
2018 $5,822
2017 $7,128
2016 $7,523
2015 $5,350
2014 $5,408
2013 $5,338
2012 $5,572
2011 $6,213
2010 $5,476
2009 $5,019
Teva Pharmaceutical Industries Quarterly Receivables
(Millions of US $)
2024-06-30 $3,766
2024-03-31 $3,456
2023-12-31 $3,408
2023-09-30 $3,385
2023-06-30 $3,539
2023-03-31 $3,435
2022-12-31 $3,696
2022-09-30 $3,730
2022-06-30 $4,471
2022-03-31 $4,253
2021-12-31 $4,529
2021-09-30 $4,046
2021-06-30 $4,488
2021-03-31 $4,572
2020-12-31 $4,581
2020-09-30 $4,385
2020-06-30 $4,545
2020-03-31 $5,189
2019-12-31 $5,676
2019-09-30 $5,254
2019-06-30 $5,260
2019-03-31 $5,108
2018-12-31 $5,822
2018-09-30 $5,665
2018-06-30 $6,061
2018-03-31 $6,289
2017-12-31 $7,128
2017-09-30 $7,424
2017-06-30 $7,320
2017-03-31 $7,264
2016-12-31 $7,523
2016-09-30 $8,071
2016-06-30 $5,374
2016-03-31 $5,188
2015-12-31 $5,350
2015-09-30 $5,275
2015-06-30 $5,568
2015-03-31 $5,508
2014-12-31 $5,408
2014-09-30 $5,410
2014-06-30 $5,389
2014-03-31 $5,275
2013-12-31 $5,338
2013-09-30 $5,191
2013-06-30 $5,305
2013-03-31 $5,416
2012-12-31 $5,572
2012-09-30 $5,782
2012-06-30 $5,430
2012-03-31 $6,056
2011-12-31 $6,213
2011-09-30 $5,605
2011-06-30 $5,469
2011-03-31 $5,576
2010-12-31 $5,476
2010-09-30 $5,228
2010-06-30 $4,985
2010-03-31 $5,136
2009-12-31 $5,019
2009-09-30 $4,689
2009-06-30 $4,376
2009-03-31 $4,134
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.679B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00